Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells

Nature Medicine

Volumn 17, Issue 11, 2011, Pages 1481-1489

  Ellingsgaard, Helga ^a   Hauselmann, Irina ^a   Schuler, Beat ^b   Habib, Abdella M ^c   Baggio, Laurie L ^d   Meier, Daniel T ^a   Eppler, Elisabeth ^b   Bouzakri, Karim ^e   Wueest, Stephan ^f   Muller, Yannick D ^g   Hansen, Ann Maria Kruse ^h   Reinecke, Manfred ^b   Konrad, Daniel ^f   Gassmann, Max ^b   Reimann, Frank ^c   Halban, Philippe A ^e   Gromada, Jesper ⁱ   Drucker, Daniel J ^d   Gribble, Fiona M ^c   Ehses, Jan A ^j   Donath, Marc Y ^a   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^g University Medical Center   (Switzerland)

^h NOVO NORDISK A S   (Denmark)

ⁱ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FURIN; GLUCAGON LIKE PEPTIDE 1; INSULIN; INTERLEUKIN 6; PROGLUCAGON; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 3; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN RELEASE; INTESTINE CELL; L CELL; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET ALPHA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENTEROENDOCRINE CELLS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-SECRETING CELLS; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHYSICAL CONDITIONING, ANIMAL; SIGNAL TRANSDUCTION;

EID: 81255157471     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2513     Document Type: Article

References (57)

1. Spranger, J. et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52, 812-817 (2003). (Pubitemid 36323590)
2. Herder, C. et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54 (suppl. 2), S11-S17 (2005). (Pubitemid 43343326)
3. Mohamed-Ali, V. et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J. Clin. Endocrinol. Metab. 82, 4196-4200 (1997). (Pubitemid 27525539)
4. Lazar, M.A. How obesity causes diabetes: not a tall tale. Science 307, 373-375 (2005). (Pubitemid 40139971)
5. Ostrowski, K., Rohde, T., Zacho, M., Asp, S. & Pedersen, B.K. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J. Physiol. (Lond.) 508, 949-953 (1998). (Pubitemid 28220743)
6. Pedersen, B.K. & Febbraio, M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 88, 1379-1406 (2008).
7. Febbraio, M.A. et al. Glucose ingestion attenuates interleukin-6 release from contracting skeletal muscle in humans. J. Physiol. (Lond.) 549, 607-612 (2003). (Pubitemid 36701770)
8. Carey, A.L. et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55, 2688-2697 (2006). (Pubitemid 44923666)
9. Mooney, R.A. Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 816-818, discussion 818-819 (2007).
10. Jansson, J.O. & Wallenius, V. Point-counterpoint: interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 821 (2007). (Pubitemid 46220919)
11. Pedersen, B.K. & Febbraio, M.A. Point: interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 814-816 (2007).
12. Weigert, C., Lehmann, R. & Schleicher, E.D. Point-counterpoint: interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 820-821, author reply 825 (2007). (Pubitemid 46220918)
13. Ellingsgaard, H. et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc. Natl. Acad. Sci. USA 105, 13163-13168 (2008).
14. Creutzfeldt, W. The incretin concept today. Diabetologia 16, 75-85 (1979). (Pubitemid 9231263)
15. Kieffer, T.J. & Habener, J.F. The glucagon-like peptides. Endocr. Rev. 20, 876-913 (1999). (Pubitemid 30647076)
16. Lund, P.K., Goodman, R.H., Dee, P.C. & Habener, J.F. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc. Natl. Acad. Sci. USA 79, 345-349 (1982). (Pubitemid 12137713)
17. Bell, G.I., Santerre, R.F. & Mullenbach, G.T. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302, 716-718 (1983). (Pubitemid 13120276)
18. Rouillé, Y., Kantengwa, S., Irminger, J.C. & Halban, P.A. Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J. Biol. Chem. 272, 32810-32816 (1997). (Pubitemid 28023615)
19. Zhu, X. et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc. Natl. Acad. Sci. USA 99, 10293-10298 (2002).
20. Rouillé, Y., Martin, S. & Steiner, D.F. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J. Biol. Chem. 270, 26488-26496 (1995).
21. Furuta, M. et al. Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. J. Biol. Chem. 276, 27197-27202 (2001).
22. Thyssen, S., Arany, E. & Hill, D.J. Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology 147, 2346-2356 (2006).
23. De León, D.D. et al. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 52, 365-371 (2003). (Pubitemid 36173191)
24. Nie, Y. et al. Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J. Clin. Invest. 105, 955-965 (2000). (Pubitemid 30203068)
25. Kilimnik, G., Kim, A., Steiner, D.F., Friedman, T.C. & Hara, M. Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic alpha-cells in mouse models of ss-cell regeneration. Islets 2, 149-155 (2010).
26. Hansen, A.M. et al. Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus-an adaptive response to hyperglycaemia? Diabetologia 54, 1379-1387 (2011).
27. Anini, Y. & Brubaker, P.L. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52, 252-259 (2003). (Pubitemid 36173176)
28. Ehses, J.A. et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56, 2356-2370 (2007). (Pubitemid 47358243)
29. Li, M. et al. Successful modulation of type 2 diabetes in db/db mice with intra-bone marrow-bone marrow transplantation plus concurrent thymic transplantation. J. Autoimmun. 35, 414-423 (2010).
30. Sabio, G. et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322, 1539-1543 (2008).
31. Wueest, S. et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J. Clin. Invest. 120, 191-202 (2010).
32. Reimann, F. et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 8, 532-539 (2008).
33. Yamaguchi, K. et al. Blockade of IL-6 signaling exacerbates liver injury and suppresses antiapoptotic gene expression in methionine choline-deficient diet-Fed db/db mice. Lab. Invest. 91, 609-618 (2011).
34. Ueda, S.Y. et al. Changes in gut hormone levels and negative energy balance during aerobic exercise in obese young males. J. Endocrinol. 201, 151-159 (2009).
35. Adam, T.C. & Westerterp-Plantenga, M.S. Activity-induced GLP-1 release in lean and obese subjects. Physiol. Behav. 83, 459-466 (2004). (Pubitemid 39586668)
36. Martins, C., Morgan, L.M., Bloom, S.R. & Robertson, M.D. Effects of exercise on gut peptides, energy intake and appetite. J. Endocrinol. 193, 251-258 (2007).
37. Chanoine, J.P. et al. GLP-1 and appetite responses to a meal in lean and overweight adolescents following exercise. Obesity (Silver Spring) 16, 202-204 (2008).
38. Dela, F., von Linstow, M.E., Mikines, K.J. & Galbo, H. Physical training may enhance beta-cell function in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 287, E1024-E1031 (2004). (Pubitemid 39382942)
39. Delmeire, D. et al. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. Biochem. Pharmacol. 68, 33-39 (2004). (Pubitemid 38746539)
40. Hinke, S.A., Hellemans, K. & Schuit, F.C. Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal. J. Physiol. (Lond.) 558, 369-380 (2004). (Pubitemid 39117588)
41. Holz, G.G., Kuhtreiber, W.M. & Habener, J.F. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361, 362-365 (1993). (Pubitemid 23041630)
42. Di Gregorio, G.B., Hensley, L., Lu, T., Ranganathan, G. & Kern, P.A. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am. J. Physiol. Endocrinol. Metab. 287, E182-E187 (2004). (Pubitemid 38856299)
43. Bosco, D. et al. Unique arrangement of alpha-and beta-cells in human islets of Langerhans. Diabetes 59, 1202-1210 (2010).
44. Rodriguez-Diaz, R. et al. Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans. Nat. Med. 17, 888-892 (2011).
45. Kieffer, T.J. et al. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585-3596 (1995).
46. Holmes, A.G. et al. Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARα and UCP2 expression in rats. J. Endocrinol. 198, 367-374 (2008).
47. Franckhauser, S. et al. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 51, 1306-1316 (2008).
48. Sadagurski, M. et al. Human IL6 enhances leptin action in mice. Diabetologia 53, 525-535 (2010).
49. Wallenius, V. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8, 75-79 (2002). (Pubitemid 34101732)
50. Weigert, C. et al. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J. Biol. Chem. 281, 7060-7067 (2006). (Pubitemid 43847469)
51. Schuler, B. et al. Optimal hematocrit for maximal exercise performance in acute and chronic erythropoietin-treated mice. Proc. Natl. Acad. Sci. USA 107, 419-423 (2010).
52. Jevdjovic, T. et al. Effects of insulin-like growth factor-I treatment on the endocrine pancreas of hypophysectomized rats: comparison with growth hormone replacement. Eur. J. Endocrinol. 151, 223-231 (2004). (Pubitemid 39207018)
53. Jevdjovic, T. et al. The effect of hypophysectomy on pancreatic islet hormone and insulin-like growth factor I content and mRNA expression in rat. Histochem. Cell Biol. 123, 179-188 (2005). (Pubitemid 40674690)
54. Sporeno, E. et al. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood 87, 4510-4519 (1996). (Pubitemid 26163491)
55. Parnaud, G. et al. Proliferation of sorted human and rat beta cells. Diabetologia 51, 91-100 (2008). (Pubitemid 50002201)
56. Gribble, F.M., Williams, L., Simpson, A.K. & Reimann, F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52, 1147-1154 (2003). (Pubitemid 36523349)
57. Rudich, A. et al. Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues. Diabetologia 46, 649-658 (2003). (Pubitemid 36808185)